ReviewFrontiers in physiology2022
The mechanisms of glycolipid metabolism disorder on vascular injury in type 2 diabetes.
Review in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Pooled it
- Preclinical evidence of ginkgo biloba extract on diabetic nephropathy: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Glycemic Status and Effect of Immediate Intensive Statin on Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Trial.CNS neuroscience & therapeutics · 2026 · on this mapTrial
- Mapping ophthalmic research on glycosylation and glycation: a PRISMA-compliant bibliometric and co‑citation analysis.Future science OA · 2026Article
- Combined assessment of triglyceride-glucose index and stress hyperglycemia ratio to predict all-cause mortality in critically ill patients with intracerebral hemorrhage.BMC neurology · 2026Article
- The Gluco-Vascular Injury Axis in Diabetic Cardiovascular Dysfunction: A Narrative Review.Cureus · 2026Review
- Glucolipid metabolic disorders and ferroptosis in diabetic ulcers: pathogenic crossroads and therapeutic opportunities.Frontiers in endocrinology · 2026Review
- Association between triglyceride glucose-body mass index and diabetic kidney disease in hospitalized patients with type 2 diabetes mellitus: a retrospective cross-sectional study.Frontiers in medicine · 2026Article
- Trained Immunity-Like Memory in Vascular Structural Cells: Metabolic-Epigenetic Reprogramming as a Driving Mechanism of Atherosclerosis and Residual Cardiovascular Risk.Journal of inflammation research · 2026Review
- NOX2-Driven Oxidative Stress Promotes EndMT and Uncouples Angiogenesis-Osteogenesis at the Bone-Implant Interface in Diabetes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cross-lag association between TyG-CVAI and frailty index: evidence from a natural population cohort in southwestern China.Frontiers in public health · 2026Article
- Cutaneous and Systemic Complications in Primary CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma.Cureus · 2025Article
- Prognostic value of triglyceride-glucose index combined with stress hyperglycemia ratio for all-cause mortality in critically ill patients with stroke.Cardiovascular diabetology · 2025Article
- Active Constituent of HQS in T2DM Intervention: Efficacy and Mechanistic Insights.International journal of molecular sciences · 2025Article
- Mechanism of TGIF1 on glycolipid metabolism disorders in mice with type 2 diabetes.BMJ open diabetes research & care · 2025Article
- Changes and Diagnostic Value of Serum CCL26 and CCR3 in T2DM with Lower Extremity Artery Disease.Vascular health and risk management · 2025Article
- Antioxidant Potential ofAdvances in pharmacological and pharmaceutical sciences · 2025Article
- Association between the triglyceride-glucose index and carotid plaque progression in patients with type 2 diabetes mellitus: a retrospective cohort study.Frontiers in endocrinology · 2025Article
- Sangyod Rice Extract Attenuates Vascular Inflammation and Injury in a Rat Model of Diabetes by Modulating the Akt/MAPK Signaling Pathway.Advances in pharmacological and pharmaceutical sciences · 2025Article
- Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways.Biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with diabetes have severe vascular complications, such as diabetic nephropathy, diabetic retinopathy, cardiovascular disease, and neuropathy. Devastating vascular complications lead to increased mortality, blindness, kidney failure, and decreased overall quality of life in people with type 2 diabetes (T2D). Glycolipid metabolism disorder plays a vital role in the vascular complications of T2D. However, the specific mechanism of action remains to be elucidated. In T2D patients, vascular damage begins to develop before insulin resistance and clinical diagnosis. Endothelial dysregulation is a significant cause of vascular complications and the early event of vascular injury. Hyperglycemia and hyperlipidemia can trigger inflammation and oxidative stress, which impair endothelial function. Furthermore, during the pathogenesis of T2D, epigenetic modifications are aberrant and activate various biological processes, resulting in endothelial dysregulation. In the present review, we provide an overview and discussion of the roles of hyperglycemia- and hyperlipidemia-induced endothelial dysfunction, inflammatory response, oxidative stress, and epigenetic modification in the pathogenesis of T2D. Understanding the connections of glucotoxicity and lipotoxicity with vascular injury may reveal a novel potential therapeutic target for diabetic vascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.